Cargando…
Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology
Pemphigus vulgaris (PV) is a rare autoimmune blistering disorder that primarily affects the skin and mucous membranes. Conventional treatments for PV, such as corticosteroids and immunosuppressive agents, have limitations in terms of efficacy and long-term safety. Monoclonal antibody therapy, specif...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361785/ https://www.ncbi.nlm.nih.gov/pubmed/37485224 http://dx.doi.org/10.7759/cureus.40734 |
_version_ | 1785076285558489088 |
---|---|
author | Khandelwal, Krishna Jajoo, Vedika Bajpai, Kshitij Madke, Bhushan Prasad, Roshan Wanjari, Mayur B Munjewar, Pratiksha K Taksande, Avinash B |
author_facet | Khandelwal, Krishna Jajoo, Vedika Bajpai, Kshitij Madke, Bhushan Prasad, Roshan Wanjari, Mayur B Munjewar, Pratiksha K Taksande, Avinash B |
author_sort | Khandelwal, Krishna |
collection | PubMed |
description | Pemphigus vulgaris (PV) is a rare autoimmune blistering disorder that primarily affects the skin and mucous membranes. Conventional treatments for PV, such as corticosteroids and immunosuppressive agents, have limitations in terms of efficacy and long-term safety. Monoclonal antibody therapy, specifically rituximab, has emerged as a promising therapeutic approach in the management of PV. This review article provides a comprehensive overview of rituximab in the treatment of PV, with a focus on its efficacy, safety profile, and immunological mechanisms of action. The article begins with an introduction to PV and the significance of monoclonal antibody therapy in dermatology. It then explores the clinical presentation and underlying immune-mediated mechanisms of PV, highlighting the autoimmune nature of the disease. The rationale for using monoclonal antibody therapy, particularly rituximab, in PV is discussed, emphasizing the limitations of conventional treatments and the concept of targeted therapy. The review delves into the efficacy and safety of rituximab based on clinical studies, evaluating disease remission rates, duration, and relapse rates. Furthermore, the immunological effects of rituximab, including B-cell depletion and modulation of the immune response, are explored in detail. Comparisons between rituximab and conventional treatment modalities in PV are made, assessing clinical outcomes, safety profiles, and long-term efficacy. Challenges and considerations in rituximab therapy are discussed, including factors influencing its efficacy, optimal dosing, treatment duration, and the need for maintenance therapy. |
format | Online Article Text |
id | pubmed-10361785 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-103617852023-07-22 Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology Khandelwal, Krishna Jajoo, Vedika Bajpai, Kshitij Madke, Bhushan Prasad, Roshan Wanjari, Mayur B Munjewar, Pratiksha K Taksande, Avinash B Cureus Medical Education Pemphigus vulgaris (PV) is a rare autoimmune blistering disorder that primarily affects the skin and mucous membranes. Conventional treatments for PV, such as corticosteroids and immunosuppressive agents, have limitations in terms of efficacy and long-term safety. Monoclonal antibody therapy, specifically rituximab, has emerged as a promising therapeutic approach in the management of PV. This review article provides a comprehensive overview of rituximab in the treatment of PV, with a focus on its efficacy, safety profile, and immunological mechanisms of action. The article begins with an introduction to PV and the significance of monoclonal antibody therapy in dermatology. It then explores the clinical presentation and underlying immune-mediated mechanisms of PV, highlighting the autoimmune nature of the disease. The rationale for using monoclonal antibody therapy, particularly rituximab, in PV is discussed, emphasizing the limitations of conventional treatments and the concept of targeted therapy. The review delves into the efficacy and safety of rituximab based on clinical studies, evaluating disease remission rates, duration, and relapse rates. Furthermore, the immunological effects of rituximab, including B-cell depletion and modulation of the immune response, are explored in detail. Comparisons between rituximab and conventional treatment modalities in PV are made, assessing clinical outcomes, safety profiles, and long-term efficacy. Challenges and considerations in rituximab therapy are discussed, including factors influencing its efficacy, optimal dosing, treatment duration, and the need for maintenance therapy. Cureus 2023-06-21 /pmc/articles/PMC10361785/ /pubmed/37485224 http://dx.doi.org/10.7759/cureus.40734 Text en Copyright © 2023, Khandelwal et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Medical Education Khandelwal, Krishna Jajoo, Vedika Bajpai, Kshitij Madke, Bhushan Prasad, Roshan Wanjari, Mayur B Munjewar, Pratiksha K Taksande, Avinash B Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology |
title | Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology |
title_full | Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology |
title_fullStr | Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology |
title_full_unstemmed | Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology |
title_short | Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology |
title_sort | rituximab in pemphigus vulgaris: a review of monoclonal antibody therapy in dermatology |
topic | Medical Education |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361785/ https://www.ncbi.nlm.nih.gov/pubmed/37485224 http://dx.doi.org/10.7759/cureus.40734 |
work_keys_str_mv | AT khandelwalkrishna rituximabinpemphigusvulgarisareviewofmonoclonalantibodytherapyindermatology AT jajoovedika rituximabinpemphigusvulgarisareviewofmonoclonalantibodytherapyindermatology AT bajpaikshitij rituximabinpemphigusvulgarisareviewofmonoclonalantibodytherapyindermatology AT madkebhushan rituximabinpemphigusvulgarisareviewofmonoclonalantibodytherapyindermatology AT prasadroshan rituximabinpemphigusvulgarisareviewofmonoclonalantibodytherapyindermatology AT wanjarimayurb rituximabinpemphigusvulgarisareviewofmonoclonalantibodytherapyindermatology AT munjewarpratikshak rituximabinpemphigusvulgarisareviewofmonoclonalantibodytherapyindermatology AT taksandeavinashb rituximabinpemphigusvulgarisareviewofmonoclonalantibodytherapyindermatology |